Leukemia Research
Volume 23, Issue 8 , Pages 741-749 , August 1999

Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bc1-2 in human myeloid leukaemia CD34 positive cells

Received 22 December 1998 ,Accepted 6 March 1999.

References 

  1. Burnett AK, Eden OB. Treatment of acute leukaemia. Lancet. 1997;349:270–275
  2. Hassan HT, Zander AR. Haematopoietic cytokines in the biology and treatment of acute myeloid leukaemia. Oncol. Rep. 1997;4:1141–1149
  3. Hassan HT, Freund M. Stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy-induced apoptosis. In:  Pieters R editors. Drug Resistance in Leukemia and Lymphoma. Harwood: Gordon and Breach; 1995;p. 123–127
  4. Al-Alami O, Sammons J, Martin JH, Hassan HT. Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and CD34 negative human leukaemia cells. Leuk. Res. 1998;22:939–945
  5. Sonneveld P. Multidrug resistance in acute myeloid leukaemia. Balliere’s. Clin. Haematol. 1996;9:185–203
  6. van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PA, Pieters R, Schoester M, Lowenberg B, et al. MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br. J. Haematol. 1997;99:76–83
  7. Hynault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M, et al. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann. Hematol. 1997;74:65–71
  8. Del Poeta G, Venditti A, Aronica G, et al.  P-glycoprotein expression in de novo acute myeloid leukemia. Leuk. Lymph. 1997;27:257–274
  9. Miwa H, Nakase K, Kita K. Biological characteristics of CD7(+) acute leukemia. Leuk. Lymph. 1996;21:239–244
  10. Wilman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research program. Semin. Hematol. 1997;34:25–33
  11. Venditti A, DelPoeta G, Buccisano F, et al.  Prognostic relevance of the expression of TdT and CD7 in 335 cases of acute myeloid leukemia. Leukemia. 1998;12:1056–1063
  12. Saxena A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am. J. Hematol. 1998;58:278–284
  13. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998;91:4480–4488
  14. Lamy T, Drenou B, Brulois I, et al.  Multidrug-resistance (MDR) activity in acute-leukemia determined by Rhodamine-123 efflux assay. Leukemia. 1995;9:1549–1555
  15. Hassan HT, Freund M. Effect of human stem cell factor on chemotherapy-induced apoptosis in myeloid leukaemia cells. Eur. J. Cancer. 1995;31:1883–1884
  16. Douglas Smith B, Bambach BJ, Vala MS, et al.  Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br. J. Haematol. 1998;102:1042–1049
  17. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukaemia cells. Nat. Med. 1996;2:574–577
  18. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumour cells from multiple forms of caspase–dependent apoptosis. Proc. Natl. Acad. Sci. USA. 1998;95:7024–7029
  19. Reed JC. Double identity for proteins of the Bc1-2 family. Nature. 1997;387:773–776
  20. Miyashita T, Reed JC. Bc1-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151–157
  21. Vario G, Innes KM, Adams JM. Bc1-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene. 1996;13:1511–1519
  22. Campos L, Oriol P, Sabido O, Guyotat D. Spontaneous expression of P-glycoprotein and Bc1-2 in acute myeloid leukemia blast cells. Leuk. Lymph. 1997;27:119–125
  23. Lohri A, van Hille B, Bacchi M, Fopp M, Joncourt F, Reuter J, et al. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bc1-2 and topoisomerase lialpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). Eur. J. Haematol. 1997;59:206–215
  24. Bradbury DA, Aldington S, Zhu YM, Russell NH. Down-regulation of bc1-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br. J. Haematol. 1996;94:671–675
  25. Pisani F, Del Poeta G, Aronica G, Venditti A, Caravita T, Amadori S. In vitro downregulation of Bc1-2 expression by all-trans retinoic acid in AML blasts. Ann. Hematol. 1997;75:145–147
  26. Freund A, Boos J, Harkin S, et al.  Augmentation of 1-β-d-arabinofuranosylcytosine (AraC) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs. Eur. J. Cancer. 1998;34:895–901
  27. Ketley NJ, Allen PD, Kelsey SM, Newland AC. Modulation of idarubicin-induced apoptosis in human acute myeloid leukaemia blasts by all-trans retinoic acid, 1,25(OH) 2 vitamin D3 and GM-CSF. Blood. 1997;90:4578–4587
  28. Kakihara T, Fukuda T, Kamishima T, et al.  Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines. Leuk. Lymph. 1997;26:369–376
  29. Estey EH. New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids. Leuk. 1998;12 (Suppl 1):S13–S15
  30. Hassan HT, Gutensohn K, Zander AR, Kuehnl P. CD34+ cell sorting and enrichment: applications in blood banking and transplantation. In:  Recktenwald D,  Radbruch A editor. Cell Separation Methods and Applications. 1998: Marcel Dekker; 1998;p. 283–292
  31. Dalal BI, Wu V, Barnett MJ. Induction failure in de novo AML is associated with expression of high levels of CD34 antigen by the leukemic blasts. Leuk. Lymph. 1997;26:299–306
  32. Fardel O, Payen L, Courtois A, et al.  Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KGla leukemic cells. Int. J. Oncol. 1998;12:315–319
  33. Bailley JD, Muller C, Jaffrezou JP, et al.  Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 1995;9:899–907
  34. Hassan HT, Veit A, Maurer HR. Synergistic interactions between differentiation inducing agents in inhibiting proliferation of HL-60 human myeloid leukaemia cells in clonogenic microassay. J. Cancer. Res. Clin. Oncol. 1991;117:227–231
  35. Ahmed N, Sammons J, Hassan HT. Bc1-2 protein in human myeloid leukaemia cells and its down-regulation during chemotherapy-induced apoptosis. Oncology Reports 1999;6(2):403–7.
  36. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bc1-2 expression in normal human bone marrow precursors and in acute myeloid leukemia. Leukemia. 1995;9:1191–1198
  37. Lauria F, Raspadori D, Rondelli D, Ventura MA, Fiacchini M, Visani G, et al. High bc1-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 1997;11:2075–2078
  38. Bradbury DA, Zhu YM, Russell NH. Bc1-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk. Lymph. 1997;24:221–228
  39. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bc1-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091–3096
  40. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bc1-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 1998;9:159–165
  41. Lotem J, Sachs L. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bc1-2 dependent and independent pathways. Cell. Growth. Differ. 1994;5:321–327
  42. Guedez L, Suresh A, Tung F, Zucali J. Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bc1-2. Eur. J. Haematol. 1996;57:149–156
  43. Klumper E, Ossenkoppele GJ, Pieters R, et al.  In vitro resistance to cytarabine, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br. J. Haematol. 1996;93:903–910
  44. Francis GE, Guimaraes JETE, Berney JJ, Wing MA. Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and AML. Leuk. Res. 1985;9:573–581
  45. Hassan HT. Synergism between differentiation agents: pre-clinical and clinical studies in myeloid leukaemia. In:  Rifkind RA editors. The Pharmacology of Cell Differentiation. Amsterdam: Elsevier; 1993;p. 277–294
  46. Venditti A, Stasi R, Del Poeta G, et al.  All-trans retinoic acid and low dose cytosine arabinoside for the treatment of poor-prognosis AML. Leukemia. 1995;9:1121–1125
  47. Hu ZB, Minden MD, McCulloch EA. Direct evidence for the participation of bc1-2 in the regulation of retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leuk. 1995;9:1667–1673
  48. Marks DC, Su GM, Davey RA, Davey MW. Extended multidrug resistance in haemopoietic cells. BrJ. Haematol. 1996;95:587–595
  49. Grey M, Borg AG, Wood P, Burgess R, Fisher A, Yin JA. Effect of cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 of cytotoxic agents in acute myeloid leukaemia. Leuk. Res. 1997;21:867–874
  50. Liu Yin JA, Wheatley K, Rees J. Burnett A. Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory AML: results of the UK MRC AML-R trial. Blood 1998;92(Suppl 1,231a):946.
  51. Douer M, Koeffler HP. Retinoic acid enhances colony stimulating factor induced clonal growth of normal human myeloid progenitor cells in vitro. Exp. Cell. Res. 1982;138:193–198
  52. Bleiberg I, Fabian I, Kantor S, Kletter Y. The effect of retinoic acid on haematopoiesis in human long term bone marrow culture. Leuk. Res. 1988;12:545–550
  53. Middelhoff G. Ball I. Retinoic acids in normal and leukaemic cell cultures: effects on monocyto- and granulocytopoiesis. Exp Hematol 1989; 17, Suppl. 665A.
  54. Benito A, Grillot D, Nunez G, Fernandez-Luna JL. Regulation and function of Bc1-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am. J. Pathol. 1995;146:481–490
  55. Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna JL. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-xL. Blood. 1996;87:3837–3843
  56. Kumakura S. Ishikura H. Tsumura H. Iwata Y. Endo J. Kobayashi S. c-Myc and Bc1-2 protein expression during the induction of apoptosis and differentiation in TNF alpha-treated HL-60 cells. Leuk Lymph 1996; 23: 383–394.
  57. Sanz C, Benito A, Silva M, Albella B, Richard C, Segovia JC, et al. The expression of Bcl-x is down-regulated during differentiation of human hematopoietic progenitor cells along the granulocyte but not the monocyte/macrophage lineage. Blood. 1997;89:3199–3204
  58. Bruel A, Karsenty E, Schmid M, McDonnell TJ, Lanotte M. Altered sensitivity to retinoidinduced apoptosis associated with changes in the subcellular distribution of Bc1-2. Exp. Cell Res. 1997;233:281–287
  59. Ray S, Bullock G, Nunez G, Tang C, Ibrado AM, Huang Y, et al. Enforced expression of Bcl-xs induces differentiation and sensitises CML-blast crisis K562 cells to 1-beta-Darabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ. 1996;7:1617–1623

PII: S0145-2126(99)00084-3

Leukemia Research
Volume 23, Issue 8 , Pages 741-749 , August 1999

Article Tools

* Image Usage & Resolution